Incorporation of albumin fusion proteins into fibrin clots <it>in vitro </it>and <it>in vivo</it>: comparison of different fusion motifs recognized by factor XIIIa
<p>Abstract</p> <p>Background</p> <p>The transglutaminase activated factor XIII (FXIIIa) acts to strengthen pathological fibrin clots and to slow their dissolution, in part by crosslinking active α<sub>2</sub>-antiplasmin (α<sub>2</sub>AP) to fib...
Main Authors: | Sheffield William P, Eltringham-Smith Louise J |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-12-01
|
Series: | BMC Biotechnology |
Online Access: | http://www.biomedcentral.com/1472-6750/11/127 |
Similar Items
-
Addition of a sequence from α<sub>2</sub>-antiplasmin transforms human serum albumin into a blood clot component that speeds clot lysis
by: Gataiance Sharon, et al.
Published: (2009-03-01) -
Fusion to Human Serum Albumin Extends the Circulatory Half-Life and Duration of Antithrombotic Action of the Kunitz Protease Inhibitor Domain of Protease Nexin 2
by: William P. Sheffield, et al.
Published: (2018-02-01) -
Factor XIIIA—expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking
by: Alessandro Porrello, et al.
Published: (2018-05-01) -
Ethacrynic acid is an inhibitor of human factor XIIIa
by: Srabani Kar, et al.
Published: (2022-06-01) -
Fibrin Clot Formation and Lysis in Plasma
by: Julie Brogaard Larsen, et al.
Published: (2020-09-01)